Excretion and metabolism of trovafloxacin in humans

Drug Metabolism and Disposition

Volumn 25, Issue 4, 1997, Pages 423-427

  Dalvie, Deepak K ^a   Khosla, Natasha ^b   Vincent, John ^b  

^a PFIZER INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG METABOLISM; DRUG STRUCTURE; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; ISOTOPE LABELING; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RADIOACTIVITY;

ADMINISTRATION, ORAL; ADULT; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FECES; FLUOROQUINOLONES; HUMANS; MALE; MASS SPECTROMETRY; NAPHTHYRIDINES; REFERENCE VALUES;

EID: 0030906391     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. T. D. Gootz and P. R. McGuirk: New quinolones in development. Expert Opin. Invest. Drugs 3, 93-114 (1994).
2. T. D. Gootz, K. E. Brighty, M. R. Anderson, B. J. Schmeider, S. L. Haskell, J. A. Sutcliffe, M. J. Castaldi, and P. R. McGuirk: In vitro activity of CP-99,219, a novel 7-(6-amino-3-azabicyclo[3.1.0]-hexyl)naphthyridone antimicrobial agent. Diagn. Microbiol. Infect. Dis. 19, 235-243 (1994).
3. B. Briggs Gooding and R. N. Jones: In vitro antimicrobial activity of CP-99,219, a novel 7-azabicyclonaphthyridone. Antimicrob. Agents Chemother. 37, 349-353 (1993).
4. H. C. Neu and N. X. Chiu: In vitro activity of the new fluoroquinolone CP-99,219. Antimicrob. Agents Chemother. 38, 2615-2622 (1994).
5. R. Teng, D. Girard, T. D. Gootz, G. Foulds, and T. E. Liston: Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone in rats, dogs and monkeys. Antimicrob. Agents Chemother. 40, 561-566 (1996).
6. D. K. Dalvie, N. Khosla K. A. Navetta, and K. E. Brighty: Metabolism of trovafloxacin, a new quinolone antibiotic, in rats and dogs. Drug Metab. Disp. 24, 1231-1240 (1996).
7. R. Teng, S. C. Harris, D. E. Nix, J. J. Schentag, G. Foulds, and T. E. Liston: Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, following administration of single oral doses to healthy male volunteers. J. Antimicrob. Chemother. 36, 385-394 (1995).
8. R. Teng, D. R. Brennan, T. G. Tensfeldt, T. E. Liston, and G. Foulds: Determination of CP-99,219, a new oral quinolone antibiotic, in biological samples by reverse-phase high performance liquid chromatography. J. Chromatogr. 675, 53-59 (1996).
9. M. Rowland and T. N. Tozer: In "Clinical Pharmacokinetics: Concepts and Applications," 3rd ed. Williams & Wilkins, Baltimore, 1995.
10. L. J. Fisher, R. L. Thies, D. Charkowski, and K. J. Donham: Formation of urinary excretion of cyproheptadine glucuronide in monkeys, chimpanzees and humans. Drug Metab. Dispos. 8, 422-424 (1980).
11. F. W. Janssen, S. K. Kirkman, C. Fenselau, M. Stogniew, B. R. Hofmann, E. M. Young, and H. W. Ruelius: Metabolic formation of N- and O-glucuronides of 3-(p-chlorophenyl)thiazolo[3,2-a]benzimidazole-2-acetic acid. Drug Metab. Dispos. 10, 599-604 (1982).
12. E. M. Faed: Properties of acyl glucuronides: implications for studies of the pharmacokinetics and metabolism of acidic drugs. Drug Metab. Rev. 15, 1213-1249 (1984).
13. B. R. Goldin: Intestinal microflora: metabolism of drugs and carcinogens. Ann. Med. 22, 43-48 (1990).
14. C. M. Cameron and R. G. Turcan: Sites of drug metabolism, prodrugs and bioactivation. In "Comprehensive Medicinal Chemistry" (J. B. Taylor, ed.), pp. 111-141. Pergamon Press, New York, 1990.
15. B. J. Dull, K. Salata, and P. Goldman: Role of intestinal flora in the acetylation of sulfasalzine metabolites. Biochem. Pharmacol. 36, 3772-3774 (1987).
16. W. R. Outman: Metabolism and the fluoroquinolones. Am. J. Med. 87 (Suppl. 6c), 37S-42S (1989).